

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

StockExchange-NSE letters/MM:651

November 18, 2016

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,


Sub : Press Release

Enclosed is a press release we propose to issue on unaudited financial results for the quarter ended on September 30, 2016.

Kindly take the same on record.

Thanking you,

Yours faithfully,
for J.B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary and Vice President - Compliance

Encl: As above



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", B WING, 4TH FLR.,

HIND CYCLE ROAD, WORLI.

MUMBAI 400 030.

PHONE : 022 2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, November 18, 2016

Unaudited Financial Results for Q 2- 2016-17

Operating margin continues to grow.

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on September 30, 2016. The highlights of Y-o-Y results prepared as per new Indian Accounting Standards are as under:

Particulars	(Rs. in crores)		
	Q2-2016-17	Q2-2015-16	Growth
Sales	293.12	284.94	2.87%
Other Operating income	8.37	6.07	
Other Income	14.65	16.32	
Total Income	316.14	307.33	
Operating Profit	48.98	40.08	22.19%
EBIT	63.62	56.40	12.80%
Profit before tax	61.59	53.05	16.09%
Profit after tax	45.20	42.15	7.24%
EPS (Rs.) (FV 2)	5.32	4.97	

Sales for the quarter registered nominal increase due to lower exports. However, operating margin at 16.71% was higher YoY.

The domestic formulations business at sales of Rs. 125.84 crores registered good growth of 12.11%, while the focus products group achieved growth of 21%. The Company has lined up several new product launches in H2, which is expected to aid growth. The contrast media products sales in domestic market at Rs. 11.11 crores registered growth of 2.26%.

The overall formulations exports at Rs. 131.35 crores were 1.26% lower than exports in corresponding period in the previous year. The exports of formulations to Rest of the World markets at Rs. 100.43 crores registered growth of 13.31% in Rupee terms, while Russia-CIS markets and certain contract manufacturing exports did not grow as off take for Russia-CIS market was impacted by poor demand conditions due to currency issues.



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

Formulations exports are impacted due to currency issues and consequent demand slow down in many markets.

US FDA has approved Company's ANDA for Oxybutynin Chloride Extended-Release Tablets USP, 5 mg, 10 mg and 15 mg. The Company expects to commence commercial supplies in the current quarter.

The API sales at Rs. 20.67 crores were 7.08% lower YoY.

The product development and miscellaneous sales income amounted to Rs.2.08 crores.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its State-of-the-Art manufacturing facilities are approved by health authorities of important regulated markets.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary and Vice President- Compliance
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 2439 5311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.